To study disorders of emotional regulation in different types of attention deficit hyperactivity disorder (ADHD) in children.

58 children suffering from ADHD, aged 12 to 15 years were divided into 2 subgroups (38 children with a combined form of ADHD and 20 children with ADHD with a predominance of inattention). The control group consisted of 30 children without manifestations of neuropsychiatric disorders. The following research methods were used in the work the SNAP-IY scale to assess the severity of the disease; the Strengths and Difficulties Questionnaire (SCT), a form for parents to assess emotional and behavioral impairments; Spielberger’s self-assessment test in the processing of Khanin to assess the level of anxiety; spectral analysis of the EEG with the construction of graphical power spectra and registration of evoked potentials (EP) with the performance of an attention test in the Go/No-Go paradigm.

The results of the study showed the presence of emotional and behavioral disorders in childrences (

<0.01) in the number of omissions of significant pairs of stimuli between healthy children and a subgroup with ADHD with a predominance of inattention, between healthy children and a subgroup with combined form ADHD. When comparing evoked EEG synchronization in the theta range under Go conditions, we found a significant decrease in this parameter in the range of 200-400 ms in the subgroup of children with ADHD with a predominance of inattention and in the subgroup of ADHD with a combined form; under No-Go conditions, a significant decrease in the magnitude of evoked EEG synchronization was revealed in a subgroup of children with combined form ADHD.

In general, the results of this study allow us to conclude that impaired cognitive control has a large impact on the development of emotional disorders in children with ADHD.

In general, the results of this study allow us to conclude that impaired cognitive control has a large impact on the development of emotional disorders in children with ADHD.

To assess the degree of satisfaction of outpatient neurologists with the results of therapy with Logacer 4 ml/1000 mg IM once daily in patients with chronic cerebral ischemia (CCI) and moderate cognitive impairment (MCI) in routine clinical practice.

The study involved 7777 patients with chronic cerebral ischemia aged 55-75 years. All patients had moderate cognitive impairment according to the MMSE scale. The patients were prescribed injection therapy with Logacer 4 ml/1000 mg 1 r/day IM for 10 days. Patient satisfaction and adherence to therapy was assessed using the Likert scale.

At the indicated doses, Logacer caused a pronounced positive effect on the neurological status and cognitive functions of patients with CCI and MCI. 3733 (49%) patients rated their satisfaction with the therapy with Logacer 3323 (43%) as 5 points – 4 points. 3988 (52%) patients rated adherence to therapy with Logacer at 5 points, 3261 (43%) patients – at 4 points.

The drug Logacer is characterized by high effectiveness and good tolerability in patients with CCI.

The drug Logacer is characterized by high effectiveness and good tolerability in patients with CCI.

Assessment of the features of cognitive impairment in patients with vascular risk factors, depending on age and gender.

The observational cross-sectional study included data from 1.651 patients aged 45 to 84 years with vascular risk factors from various regions of the Russian Federation. The presence and nature of cognitive impairment (CI) were detected using the MOCA test, taking into account the total MOCA score and MOCA indexes evaluating violations of individual cognitive functions (memory, attention, speech, executive and visual-constructive functions, orientation).

CI was detected in 89.2% of the surveyed (the total score of the MOCA <26). In middle-aged patients, 45-49 years old, executive functions and attention suffered more. The negative dynamics of CI significantly worsened in the age range of 70-75 years, statistically significantly increased every subsequent five years and was manifested by deterioration both in the mnestic sphere and in other cognitive domains. Statistically significant differences in the indicators of the total MOCA score in women and men were revealed at the age of 80-84 years (16.1 vs. 13.8 points, respectively,

=0.0279). By the age of 80-84, women had higher indicators of attention (

=0.025) and orientation (

=0.028) than men of the same age.

The data obtained make it possible to identify patients, regardless of gender, under the age of 70 as an important target group for the treatment and more aggressive prevention of CI.

The data obtained make it possible to identify patients, regardless of gender, under the age of 70 as an important target group for the treatment and more aggressive prevention of CI.

To identify clinical and laboratory indicators associated with the development of chronic musculoskeletal pain syndrome in young and middle-aged patients with degenerative changes of the spine.

The study included 103 patients (59 women and 44 men) with a mean age 42 [36; 47] years with chronic musculoskeletal back pain. To verify degenerative changes of the spine, MRI was performed using Magnetom Symphony (Siemens; Germany), Magnetom Verio (Siemens; Germany) devices. The intensity of the pain syndrome, the neuropathic component of pain sensations, and affective disorders were assessed. Blood levels of osteocalcin, parathyroid hormone, thyroid stimulating hormone were determined using an immunochemiluminescent analyzer Immulite 2000 (Siemens, USA), vitamin D – using an immunochemical analyzer Architect i2000SR (Abbott, USA), vitamin PP and 17-hydroxyprogesterone by sandwich-type ELISA on a plate reader VICTOR 2 (Perken Elmer, USA). The levels of interleukin-1β, interleukin-6 and interleukin-8 and tumor necain group may be associated with desorganized bone remodeling and increased bone resorbtion.In the last decades autism diagnosis has shown great differences in prevalence studies, apparently related to methods applied in the evaluation of children with relational and\or communicative difficulties. In the present study a literature evaluation is conducted, suggesting the advantages of an extensive and accurate clinical evaluation of the child with his family, possibly supported by tests like CARS, convergent with this approach and, in contrast, risks related to the use of semi-structured tests. Some of the last-mentioned tests have been considered, decades ago, as `golden standard‘ for diagnosis, but this was probably an unfortunate illusion, which may have favoured many inappropriate diagnoses. The history of the concept of autism is described, split between the suggestion of dealing with `one‘ condition and, alternatively, with a behaviour related to different syndromes and disorders. Various examples on positive evolution of this condition are reported, supporting the view of autism as an abnormal behaviour, usually comorbid with other conditions, in some cases curable and amenable to correction up to the removal of the diagnosis.The review discusses cognitive functions in late-onset schizophrenia and very late-onset schizophrenia-like psychosis compared to cognition in normal aging, early-onset schizophrenia, and neurodegenerative diseases. The problem of the dynamics of the state of the cognitive functions in patients with late-onset schizophrenic psychoses is highlighted, and prospects for further research are discussed. Patients with late-onset schizophrenic psychosis are characterized by more pronounced cognitive deficits compared to normal aging, but less severe than cognitive changes observed in early-onset schizophrenia. Late-onset schizophrenia may be a heterogeneous condition in terms of cognitive dysfunction.

Determination of the dose-dependent effect of the Teraligen for various nosological forms of disorders in psychiatric practice and general medicine.

Analysis of 98 publications included in the database of the RISC (2012-2021) with the identification of disorders (according to ICD-10) in which Teraligen is prescribed or can be used (in adults and children from the age of 7).

Despite a rather long and successful history use, research work on the study drug Teraligen continues. Currently Teraligen is widely and actively used by doctors of various specialties in the psychiatry, neurology, pediatrics, gerontology, internal medicine, gastroenterology, gynecology, cardiology, endocrinology and other disciplines. The drug is presented in several release forms Teraligen 5 mg tablets; Teraligen retard 20 mg; Teraligen solution for intravenous injections. Teraligen is characterized by the following psychotropic effects anxiolytic (++ – a distinct, moderately pronounced effect); sedative (++); hypnotic (++); antidee other «small» neuroleptics/antipsychotics with a predominantly sedative effect, the drug can be used to correct neuroleptics-prolongs side effects with dominant manifestations in the form of anxiety, irritability and insomnia.Anxiety and depressive disorders are characterized with frequent co-occurance. Depression comorbid to anxiety disorder increases severity of main disorder, aggravates it`s clinical course, worsens social functioning of the patients and decreases life quality, results resistance to therapy and increases the probability of suicidal attempts. In patients with depressive disorders onset of anxiety disorder results increased severity of disorder and decrease in quality of remission. There are different opinions on nature and phenomenology of comorbidity of anxiety and depressive disorders. There are biological and psychological factors of risk of comorbidity. Some scientists consider comorbid disorders to be independent and not to effect each other; others pay attention at common anatomic basis of comorbid disorders, which explains manifestation of comorbid disorder. Hierarchical analysis of clinical features of comorbid disorders favors nosological approach to understanding of comorbidity, and implicates the need for inclusion of transdiagnostic elements. Some authors consider comorbid disorders to be separate type of disorder, characterized with special dynamics of syndromes which reveals transformation of one disorder into another. Phenomenon of comorbidity can be described as part of concept of disease spread which estimates important role of bridge psychic states. selleck chemicals Considering clinical features of comorbid disorders, difficulties of their therapy based on concepts of phenomenology of comorbid depressive and anxiety disorders recommendations on prevention, early diagnosing and managing of comorbid disorders were elaborated. Psychotherapy (including CBT, which demonstrated high efficiency) is an essential element of treatment of comorbid depressive and anxiety disorders. Psychotherapy is supposed to be correcting personality traits, cognitive mistakes and maladaptive strategies of coping with disorder, which support the comorbidity.The article presents data on the conditions of use and efficacy of botulinum toxin preparations, oral muscle relaxants, selective serotonin reuptake inhibitors, acetylcholinesterase inhibitors and a glutamatergic transmission modulator in post-stroke neurorehabilitation, and provides recommendations for their rational and safe use. The clinical efficacy of Mexidol, which has a polymodal effect on a wide range of post-stroke disorders, especially in long-term sequential therapy, is discussed. A complex use of post-stroke rehabilitation methods with the determination of individual tactics based on the clinical picture of the patient and the defined rehabilitation goals is recommended. The inclusion of Mexidol in the complex therapy of patients with stroke consequences for tasks related to improving motor, affective and cognitive functions and self-care and quality of life looks promising. It is necessary to continue high-quality clinical studies to assess the pharmaceuticals efficacy in relation to post-stroke disorders.